CGH-2466
| CGH-2466 | |
|---|---|
| [[File:|frameless|220px|alt=|Chemical structure of CGH-2466]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
CGH-2466 is a novel investigational compound currently under research for its potential therapeutic applications in the treatment of neurodegenerative diseases. This compound has shown promise in preclinical studies, particularly in models of Alzheimer's disease and Parkinson's disease.
Mechanism of Action
CGH-2466 is believed to exert its effects through modulation of the neurotransmitter systems in the brain. It acts as a selective agonist at the serotonin receptor subtype 5-HT6, which is implicated in cognitive processes. By enhancing serotonergic activity, CGH-2466 may improve cognitive function and slow the progression of neurodegenerative symptoms.
Pharmacokinetics
The pharmacokinetic profile of CGH-2466 has been characterized in animal models. It exhibits good oral bioavailability and penetrates the blood-brain barrier effectively. The compound is metabolized primarily in the liver and has a half-life conducive to once-daily dosing.
Clinical Trials
CGH-2466 is currently in Phase II clinical trials. Initial results have demonstrated a favorable safety profile and preliminary efficacy in improving cognitive function in patients with mild to moderate Alzheimer's disease. Further studies are ongoing to evaluate its long-term effects and potential benefits in other neurodegenerative conditions.
Potential Side Effects
As with any investigational drug, CGH-2466 may have side effects. Commonly reported adverse effects in clinical trials include mild gastrointestinal disturbances, headache, and dizziness. Serious adverse events have been rare.
Research and Development
The development of CGH-2466 is being spearheaded by a consortium of academic institutions and pharmaceutical companies. The research is funded by grants from various governmental and non-governmental organizations dedicated to advancing treatments for neurodegenerative diseases.
Future Directions
Future research on CGH-2466 will focus on elucidating its precise mechanism of action, optimizing its pharmacological properties, and expanding its therapeutic indications. There is also interest in exploring its potential synergistic effects when used in combination with other neuroprotective agents.
Also see
- Neurodegenerative disease
- Alzheimer's disease
- Parkinson's disease
- Serotonin receptor
- Blood-brain barrier
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
